Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AIM ImmunoTech Inc. Director's Dealing 2016

Jun 23, 2016

35334_dirs_2016-06-23_3f59ea04-358b-42ce-9daf-e859289fd921.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2016-06-21

Reporting Person: MITCHELL WILLIAM M (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2016-06-21 Options to Buy Common Stock $0.13 A 150000 Acquired 2026-06-21 Common Stock (150000) Direct